Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Novo Nordisk A/S (NVO) vs Pfizer Inc. (PFE)

Novo Nordisk A/S and Pfizer Inc. are both Drug Manufacturers General companies. Pfizer Inc. is the larger, with a market value of $161.7B against $129.3B — 1.3× the size. Novo Nordisk A/S trades at the lower P/E: 9.5× against 37.7×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against −0.21%. Novo Nordisk A/S has the higher net margin (35.5% vs 6.80%) and the higher return on invested capital (28.7% vs 6.30%). Both pay a dividend; Pfizer Inc. yields more (6.18% vs 1.36%). Across the 23 metrics below, Novo Nordisk A/S leads on 15 and Pfizer Inc. on 8.

Valuation

Metric NVO PFE Drug Manufacturers General median
P/E 9.49 37.71 24.72
P/S 3.34 2.56 3.35
P/B 5.00 1.91 5.00
Price to free cash flow 22.61 16.04 17.68
EV/EBITDA 7.04 10.53 13.91
EV/Sales 3.62 3.37 3.95
Earnings yield 10.54% 2.65% 2.92%
Free cash flow yield 4.42% 6.24% 4.42%

Profitability

Metric NVO PFE Drug Manufacturers General median
Gross margin 80.73% 73.18% 72.77%
Operating margin 43.36% 21.70% 18.90%
Net margin 35.47% 6.80% 8.27%
Free cash flow margin 14.79% 17.25% 17.25%
Return on equity 60.84% 4.97% 6.97%
Return on assets 22.00% 2.13% 2.76%
Return on invested capital 28.67% 6.30% 6.30%

Growth

Metric NVO PFE Drug Manufacturers General median
Revenue growth (TTM) 13.15% (0.21%) 6.79%
EPS growth (last fiscal year) 6.40% (3.55%) —
Revenue growth, 5-year CAGR 19.20% 8.48% 3.98%
Net income growth, 5-year CAGR 19.16% (3.23%) 0.42%

Health

Metric NVO PFE Drug Manufacturers General median
Debt to equity 0.63 0.74 0.63
Current ratio 0.87 1.27 1.32
Net debt to EBITDA 0.65 2.46 1.15

Dividend

Metric NVO PFE Drug Manufacturers General median
Dividend yield 1.36% 6.18% 3.57%
Payout ratio 0.41 0.43 0.53

Size

Metric NVO PFE Drug Manufacturers General median
Market cap 129.28b 161.70b 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack